Menu Search
Equities

USANA Health Sciences Inc

USJ:DUS

USANA Health Sciences Inc

Actions
  • Price (EUR)33.60
  • Today's Change-0.600 / -1.75%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 16 2024 15:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year USANA Health Sciences Inc's revenues fell -7.77% from 998.60m to 921.01m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 69.35m to 63.79m, a -8.02% decrease.
Gross margin80.77%
Net profit margin6.29%
Operating margin9.64%
Return on assets8.93%
Return on equity11.23%
Return on investment10.84%
More ▼

Cash flow in USDView more

In 2023, USANA Health Sciences Inc increased its cash reserves by 14.39%, or 41.93m. The company earned 70.64m from its operations for a Cash Flow Margin of 7.67%. In addition the company used 11.98m on investing activities and also paid 14.24m in financing cash flows.
Cash flow per share3.54
Price/Cash flow per share10.72
Book value per share26.89
Tangible book value per share24.50
More ▼

Balance sheet in USDView more

USANA Health Sciences Inc has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 330.42m.
Current ratio4.03
Quick ratio3.44
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)-8.43
EPS (TTM) vs
TTM 1 year ago		-12.89
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.